{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:42:11Z","timestamp":1793029331824,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,10]],"date-time":"2027-08-10T00:00:00Z","timestamp":1817856000000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K24268"],"award-info":[{"award-number":["23K24268"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03007"],"award-info":[{"award-number":["22H03007"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025019","name":"Support for Pioneering Research Initiated by the Next Generation","doi-asserted-by":"publisher","award":["JPMJSP2119"],"award-info":[{"award-number":["JPMJSP2119"]}],"id":[{"id":"10.13039\/501100025019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nucmedbio.2026.109665","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:22:51Z","timestamp":1786029771000},"page":"109665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reducing renal radioactivity of radiolabeled tetravalent RGD peptides via cleavable linkers for targeted radionuclide therapy"],"prefix":"10.1016","volume":"160-161","author":[{"given":"Thanakrit","family":"Suebboonprathueng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109665_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061733","article-title":"Clinical advances and perspectives in targeted radionuclide therapy","volume":"15","author":"Lepareur","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25071743","article-title":"Targeted radionuclide therapy of prostate cancer\u2014from basic research to clinical perspectives","volume":"25","author":"Czerwi\u0144ska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2967\/jnumed.123.267023","article-title":"Absorbed dose\u2013response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE: one step closer to personalized medicine","volume":"65","author":"Hebert","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26061792","article-title":"PET diagnostic molecules utilizing multimeric cyclic RGD peptide analogs for imaging integrin \u03b1v\u03b23 receptors","volume":"26","author":"Liolios","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/anie.200502794","article-title":"Synthetic multivalent ligands as probes of signal transduction","volume":"45","author":"Kiessling","year":"2006","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.molmed.2020.12.006","article-title":"Multivalent probes in molecular imaging: reality or future?","volume":"27","author":"B\u00f6hmer","year":"2021","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0035","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3","article-title":"Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors","volume":"37","author":"Mammen","year":"1998","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0040","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/bph.12106","article-title":"Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands","volume":"168","author":"Vauquelin","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070978","article-title":"Are Integrins still practicable targets for anti-cancer therapy?","volume":"11","author":"Alday-Parejo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9090116","article-title":"Exploring the role of RGD-recognizing integrins in cancer","volume":"9","author":"Nieberler","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071711","article-title":"RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field","volume":"13","author":"Ludwig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0065","first-page":"1707","article-title":"microPET imaging of glioma integrin \u03b1v\u03b23 expression using 64Cu-labeled tetrameric RGD peptide","volume":"46","author":"Wu","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0070","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s00259-021-05333-z","article-title":"18F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients comparison with 18F-FDG","volume":"49","author":"Wu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0075","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2967\/jnumed.122.264383","article-title":"Prospective phase II trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PETCT imaging of integrin \u03b1v\u03b23 for prognostication in patients with neuroendocrine neoplasms","volume":"64","author":"Carlsen","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1083\/jcb.200503017","article-title":"The mechanisms and dynamics of \u03b1v\u03b23 integrin clustering in living cells","volume":"171","author":"Cluzel","year":"2005","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0085","doi-asserted-by":"crossref","first-page":"16008","DOI":"10.1021\/acs.jmedchem.1c01396","article-title":"Influence of linker molecules in hexavalent RGD peptides on their multivalent interactions with integrin \u03b1v\u03b23","volume":"64","author":"Mizuno","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0090","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1021\/acs.jmedchem.4c03007","article-title":"Design of a tetravalent RGD peptide capable of simultaneous binding with multiple integrin \u03b1v\u03b23 for targeted radionuclide therapy","volume":"68","author":"Mizuno","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0095","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1667\/RR3105","article-title":"Renal toxicity after radionuclide therapy","volume":"161","author":"Lambert","year":"2004","journal-title":"Radiat Res"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0100","article-title":"Nephrotoxicity after radionuclide therapies","volume":"15","author":"Parihar","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0105","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","article-title":"86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) \u2013a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion","volume":"30","author":"Jamar","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cbpa.2021.06.008","article-title":"Reducing the renal retention of low- to moderatemolecular-weight radiopharmaceuticals","volume":"63","author":"Chigoho","year":"2021","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0115","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1349-7006.2012.02286.x","article-title":"Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin avb3 targeting using single photon emission computed tomography and optical imaging","volume":"13","author":"Briat","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nucmedbio.2003.07.003","article-title":"Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation","volume":"31","author":"Chen","year":"2004","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1021\/bc300428b","article-title":"Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments","volume":"24","author":"Akizawa","year":"2013","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.nucmedbio.2020.03.001","article-title":"Renal brush border strategy: a developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides","volume":"92","author":"Arano","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0135","first-page":"262","article-title":"Strategies to reduce renal radioactivity levels of antibody fragments","volume":"42","author":"Arano","year":"1998","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0140","first-page":"128","article-title":"Chemical design of radiolabeled antibody fragments for low renal radioactivity levels","volume":"59","author":"Arano","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0145","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41598-020-80275-4","article-title":"Autophagy facilitates type I collagen synthesis in periodontal ligament cells","volume":"11","author":"Nakamura","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0150","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.analchem.6b00976","article-title":"Where did the linker-payload go? A quantitative investigation on the destination of the released linker-payload from an antibody-drug conjugate with a maleimide linker in plasma","volume":"88","author":"Wei","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0155","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/1535-7163.MCT-16-0040","article-title":"\u03b1v\u03b23 integrin-targeted radionuclide therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4","volume":"15","author":"Jin","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020476","article-title":"Cysteine cathepsins as therapeutic targets in immune regulation and immune disorders","volume":"11","author":"Senjor","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071679","article-title":"The ins and outs of cathepsins: physiological function and role in disease management","volume":"9","author":"Yadati","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0175","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1091\/mbc.e07-02-0101","article-title":"Neonatal fc receptor mediates internalization of fc in transfected human endothelial cells","volume":"19","author":"Goebl","year":"2008","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01393","article-title":"Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation","volume":"11","author":"Junker","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.nucmedbio.2026.109665_bb0185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","article-title":"Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view","volume":"34","author":"Boswell","year":"2007","journal-title":"Nucl Med Biol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:26:32Z","timestamp":1793028392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S0969805126000648"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109665","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing renal radioactivity of radiolabeled tetravalent RGD peptides via cleavable linkers for targeted radionuclide therapy","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109665"}}